Riverwater Partners LLC Sells 8,174 Shares of LeMaitre Vascular, Inc. $LMAT

Riverwater Partners LLC lowered its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 28.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 21,001 shares of the medical instruments supplier’s stock after selling 8,174 shares during the period. Riverwater Partners LLC’s holdings in LeMaitre Vascular were worth $1,838,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Parkside Financial Bank & Trust lifted its holdings in LeMaitre Vascular by 1,913.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 287 shares during the period. First Horizon Corp acquired a new position in shares of LeMaitre Vascular in the third quarter worth approximately $39,000. Geneos Wealth Management Inc. boosted its holdings in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC bought a new stake in LeMaitre Vascular in the second quarter valued at approximately $47,000. Finally, Laurel Wealth Advisors LLC increased its position in LeMaitre Vascular by 8,205.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,495 shares of the medical instruments supplier’s stock valued at $124,000 after purchasing an additional 1,477 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of analyst reports. Roth Mkm reaffirmed a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Finally, Barrington Research reiterated an “outperform” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $100.20.

LeMaitre Vascular Trading Up 1.3%

Shares of LMAT stock opened at $85.28 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of 36.76, a PEG ratio of 1.87 and a beta of 0.68. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $105.55. The company has a 50-day simple moving average of $84.31 and a two-hundred day simple moving average of $87.49.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The company had revenue of $61.05 million during the quarter, compared to analyst estimates of $62.18 million. During the same quarter last year, the business posted $0.49 EPS. LeMaitre Vascular’s quarterly revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.